Across TCGA pan-cancer cohorts, SULT1C2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SULT1C2 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher SULT1C2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SULT1C2 expression acts as an unfavorable survival marker.

DLBC, PAAD, and UCEC are the cancer types where SULT1C2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
PAAD	OS	Median	All	0.107	0.640	<.001	24	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SULT1C2 tumor-vs-normal RNA expression · all SULT1C2 data types